Bristol Myers Squibb Gross Margin 2010-2022 | BMY

Current and historical gross margin for Bristol Myers Squibb (BMY) over the last 10 years. The current gross profit margin for Bristol Myers Squibb as of March 31, 2022 is %.
Bristol Myers Squibb Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2022-03-31 $46.96B $37.39B 79.62%
2021-12-31 $46.39B $36.45B 78.57%
2021-09-30 $45.47B $34.97B 76.92%
2021-06-30 $44.38B $33.68B 75.88%
2021-03-31 $42.81B $31.86B 74.42%
2020-12-31 $42.52B $30.75B 72.31%
2020-09-30 $39.40B $28.04B 71.18%
2020-06-30 $34.86B $24.22B 69.47%
2020-03-31 $31.01B $21.09B 68.02%
2019-12-31 $26.15B $18.07B 69.10%
2019-09-30 $24.17B $16.98B 70.23%
2019-06-30 $23.86B $16.80B 70.43%
2019-03-31 $23.29B $16.58B 71.20%
2018-12-31 $22.56B $16.09B 71.34%
2018-09-30 $22.04B $15.58B 70.69%
2018-06-30 $21.60B $15.21B 70.42%
2018-03-31 $21.04B $14.71B 69.90%
2017-12-31 $20.78B $14.76B 71.05%
2017-09-30 $20.57B $14.75B 71.71%
2017-06-30 $20.24B $14.69B 72.60%
2017-03-31 $19.97B $14.78B 74.04%
2016-12-31 $19.43B $14.46B 74.42%
2016-09-30 $18.47B $13.96B 75.56%
2016-06-30 $17.62B $13.31B 75.55%
2016-03-31 $16.91B $12.80B 75.67%
2015-12-31 $16.56B $12.65B 76.39%
2015-09-30 $16.53B $12.61B 76.27%
2015-06-30 $16.38B $12.55B 76.60%
2015-03-31 $16.11B $12.30B 76.34%
2014-12-31 $15.88B $11.95B 75.24%
2014-09-30 $16.06B $11.82B 73.61%
2014-06-30 $16.21B $11.80B 72.81%
2014-03-31 $16.37B $11.84B 72.36%
2013-12-31 $16.39B $11.77B 71.81%
2013-09-30 $16.14B $11.71B 72.60%
2013-06-30 $15.81B $11.57B 73.22%
2013-03-31 $16.20B $11.83B 73.03%
2012-12-31 $17.62B $13.01B 73.84%
2012-09-30 $18.88B $13.98B 74.04%
2012-06-30 $20.49B $15.17B 74.03%
2012-03-31 $21.48B $15.93B 74.13%
2011-12-31 $21.24B $15.65B 73.65%
2011-09-30 $20.90B $15.26B 72.99%
2011-06-30 $20.35B $14.84B 72.89%
2011-03-31 $19.69B $14.37B 73.01%
2010-12-31 $19.48B $14.21B 72.92%
2010-09-30 $19.41B $14.11B 72.71%
2010-06-30 $19.40B $14.06B 72.50%
2010-03-31 $19.29B $14.01B 72.63%
2009-12-31 $18.81B $13.67B 72.67%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $163.981B $46.385B
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products. It offers products which includes hematology, oncology, cardiovascular and immunology. Bristol-Myers Squibb Company, formerly known as Bristol-Myers Company, is based in New York.
Stock Name Country Market Cap PE Ratio
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
Biohaven Pharmaceutical Holding (BHVN) United States $9.996B 0.00
QIAGEN (QGEN) Netherlands $9.982B 15.76
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.424B 6.09
Arcus Biosciences (RCUS) United States $1.353B 34.31
Myovant Sciences (MYOV) United Kingdom $0.930B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.444B 0.00
Gelesis Holdings (GLS) United States $0.355B 0.00
Zymeworks (ZYME) Canada $0.299B 0.00
Ambrx Biopharma (AMAM) United States $0.138B 0.00
Enzo Biochem (ENZ) United States $0.118B 24.20
SQZ Biotechnologies (SQZ) United States $0.090B 0.00